^
PD-L1 negative
Melanoma
pembrolizumab + ipilimumab
Sensitive
:
C3
J Clin Oncol - 1wk
BRAF V600K + CDKN2A deletion + RB1 expression
Melanoma
vemurafenib + palbociclib
Sensitive
:
C3
Clin Cancer Res - 1wk
BRAF V600E + CDKN2A deletion + RB1 expression
Melanoma
vemurafenib + palbociclib
Sensitive
:
C3
Clin Cancer Res - 1wk
ARAF mutation + NRAS mutation
Melanoma
HM95573
Resistant
:
D
Nature - 1wk
BRAF V600E
Melanoma
Immunotherapy
Resistant
:
C3
SID 2021 - 3wk
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
dabrafenib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600K
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
pembrolizumab
Sensitive
:
A1
BRAF V600E
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600E
Melanoma
vemurafenib
Sensitive
:
A1
BRAF V600E
Melanoma
trametinib
Sensitive
:
A1
No biomarker
Melanoma
nivolumab
Sensitive
:
A1
No biomarker
Melanoma
ipilimumab
Sensitive
:
A1
No biomarker
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
ipilimumab
Sensitive
:
A1
PD-L1 underexpression
Melanoma
nivolumab + ipilimumab
Sensitive
:
A1
BRAF V600
Melanoma
dabrafenib
Sensitive
:
A1
No biomarker
Melanoma
trametinib
Resistant
:
A1
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib
Sensitive
:
A1
BRAF V600K
Melanoma
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib
Sensitive
:
A1
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive
:
A1
BRAF V600K
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600E
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our